Veterinary Medicine Information website

EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Authorised
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Download as PDF

Product identification

Medicine name:
EURICAN DAPPI LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
Active substance:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain CGF 2004/75, Live
    4.70
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain BA5, Live
    4.00
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    4.90
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    2.50
    log10 50% cell culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Plastic box of 10 vials of lyophilisate (1 dose)
  • Plastic box of 50 vials of lyophilisate (1 dose)
  • Plastic box of 100 vials of lyophilisate (1 dose)
  • Plastic box of 10 vials of solvent (1 ml)
  • Plastic box of 50 vials of solvent (1 ml)
  • Plastic box of 100 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)
  • Plastic box of 100 vials of lyophilisate (1 dose) and 100 vials of solvent (1 ml)
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France SCS
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V499164
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0306/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Malta
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2026
Download
Dutch (PDF)
Published on: 13/03/2026
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2026
Download
German (PDF)
Published on: 13/03/2026
Download
Dutch (PDF)
Published on: 13/03/2026
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 13/03/2026
Download
German (PDF)
Published on: 13/03/2026
Download
Dutch (PDF)
Published on: 13/03/2026
Download

Combined File of all Documents

English (PDF)
Published on: 13/03/2026
Download

eu-puar-frv0306001-mr-rpe792-en.pdf

English (PDF)
Published on: 13/03/2026
Download